MTOR and cardiomyopathy: Nevertheless, clinicians have been hesitant to prescribe lifelong mTOR inhibitors because of their immunosuppressive properties and the lack of supporting evidence for mTOR inhibitors efficiency and safety in cardiomyopathy and in patients with ADKH-RRAGD.